Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 1
1998 2
1999 1
2000 2
2002 1
2003 5
2004 6
2005 3
2006 8
2007 8
2008 13
2009 4
2010 3
2011 3
2012 2
2013 3
2014 5
2015 5
2016 1
2017 3
2018 1
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 15728778

73 results
Results by year
Filters applied: . Clear all
Page 1
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Wang X, Gattone V 2nd, Harris PC, Torres VE. Wang X, et al. J Am Soc Nephrol. 2005 Apr;16(4):846-51. doi: 10.1681/ASN.2004121090. Epub 2005 Feb 23. J Am Soc Nephrol. 2005. PMID: 15728778 Free article.
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Gattone VH 2nd, Wang X, Harris PC, Torres VE. Gattone VH 2nd, et al. Nat Med. 2003 Oct;9(10):1323-6. doi: 10.1038/nm935. Epub 2003 Sep 21. Nat Med. 2003. PMID: 14502283
Role of vasopressin antagonists.
Torres VE. Torres VE. Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Clin J Am Soc Nephrol. 2008. PMID: 18434616 Free article. Review.
Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Masyuk TV, et al. Gastroenterology. 2007 Mar;132(3):1104-16. doi: 10.1053/j.gastro.2006.12.039. Epub 2006 Dec 20. Gastroenterology. 2007. PMID: 17383431
Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, Avner ED. Torres VE, et al. Kidney Int. 2004 Nov;66(5):1766-73. doi: 10.1111/j.1523-1755.2004.00952.x. Kidney Int. 2004. PMID: 15496147 Free article.
Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ. Nagao S, et al. Kidney Int. 2003 Feb;63(2):427-37. doi: 10.1046/j.1523-1755.2003.00755.x. Kidney Int. 2003. PMID: 12631108 Free article.
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. Yamamura Y, et al. J Pharmacol Exp Ther. 1998 Dec;287(3):860-7. J Pharmacol Exp Ther. 1998. PMID: 9864265
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.
Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Yamaguchi T, et al. J Biol Chem. 2004 Sep 24;279(39):40419-30. doi: 10.1074/jbc.M405079200. Epub 2004 Jul 19. J Biol Chem. 2004. PMID: 15263001 Free article.
Therapies to slow polycystic kidney disease.
Torres VE. Torres VE. Nephron Exp Nephrol. 2004;98(1):e1-7. doi: 10.1159/000079926. Nephron Exp Nephrol. 2004. PMID: 15361692 Review.
Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S, Pisani A. Sabbatini M, et al. Am J Physiol Renal Physiol. 2014 May 15;306(10):F1243-50. doi: 10.1152/ajprenal.00694.2013. Epub 2014 Mar 19. Am J Physiol Renal Physiol. 2014. PMID: 24647711 Free article.
73 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page